Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Giulia Chiabotto

Showing results (21-30 of 28) with videos related to

Pageof 3
Sort By:
You have reached the last page of results.This site can display upto 28 results.
Plos One|May 10, 2023
Extracellular vesicles from human plasma for biomarkers discovery: Impact of anticoagulants and isolation techniquesValentina Bettio, Eleonora Mazzucco, Annamaria Antona, et al.
Cancers|December 24, 2021
PARP1 Inhibitor and Trabectedin Combination Does Not Increase Tumor Mutational Burden in Advanced Sarcomas-A Preclinical and Translational StudyYmera Pignochino, Giovanni Crisafulli, Giorgia Giordano, et al.
Cancers|June 14, 2020
Pazopanib and Trametinib as a Synergistic Strategy against Osteosarcoma: Preclinical Activity and Molecular InsightsGiulia Chiabotto, Giovanni Grignani, Maja Todorovic, et al.
EMBO Molecular Medicine|May 19, 2026
WEE1 kinase inhibition to overcome acquired resistance to targeted therapies in colorectal cancerKristi Buzo, Laura Bizzozero, Marilena Lentini, et al.
Molecular Cancer|April 30, 2017
PARP1 expression drives the synergistic antitumor activity of trabectedin and PARP1 inhibitors in sarcoma preclinical modelsYmera Pignochino, Federica Capozzi, Lorenzo D'Ambrosio, et al.
Oncotarget|November 10, 2015
Isolation and characterization of renal cancer stem cells from patient-derived xenograftsMeriem Hasmim, Stefania Bruno, Sandy Azzi, et al.
Frontiers in Oncology|September 16, 2022
DNA damage response and repair genes in advanced bone and soft tissue sarcomas: An 8-gene signature as a candidate predictive biomarker of response to trabectedin and olaparib combinationAlessandra Merlini, Maria Laura Centomo, Giulio Ferrero, et al.
The Lancet. Oncology|September 16, 2018
Trabectedin and olaparib in patients with advanced and non-resectable bone and soft-tissue sarcomas (TOMAS): an open-label, phase 1b study from the Italian Sarcoma GroupGiovanni Grignani, Lorenzo D'Ambrosio, Ymera Pignochino, et al.
Pageof 3

Showing results (21-30 of 28) with videos related to

Sort By:
Pageof 3
You have reached the last page of results.This site can display upto 28 results.
Plos One|May 10, 2023
Extracellular vesicles from human plasma for biomarkers discovery: Impact of anticoagulants and isolation techniquesValentina Bettio, Eleonora Mazzucco, Annamaria Antona, et al.
Cancers|December 24, 2021
PARP1 Inhibitor and Trabectedin Combination Does Not Increase Tumor Mutational Burden in Advanced Sarcomas-A Preclinical and Translational StudyYmera Pignochino, Giovanni Crisafulli, Giorgia Giordano, et al.
Cancers|June 14, 2020
Pazopanib and Trametinib as a Synergistic Strategy against Osteosarcoma: Preclinical Activity and Molecular InsightsGiulia Chiabotto, Giovanni Grignani, Maja Todorovic, et al.
EMBO Molecular Medicine|May 19, 2026
WEE1 kinase inhibition to overcome acquired resistance to targeted therapies in colorectal cancerKristi Buzo, Laura Bizzozero, Marilena Lentini, et al.
Molecular Cancer|April 30, 2017
PARP1 expression drives the synergistic antitumor activity of trabectedin and PARP1 inhibitors in sarcoma preclinical modelsYmera Pignochino, Federica Capozzi, Lorenzo D'Ambrosio, et al.
Oncotarget|November 10, 2015
Isolation and characterization of renal cancer stem cells from patient-derived xenograftsMeriem Hasmim, Stefania Bruno, Sandy Azzi, et al.
Frontiers in Oncology|September 16, 2022
DNA damage response and repair genes in advanced bone and soft tissue sarcomas: An 8-gene signature as a candidate predictive biomarker of response to trabectedin and olaparib combinationAlessandra Merlini, Maria Laura Centomo, Giulio Ferrero, et al.
The Lancet. Oncology|September 16, 2018
Trabectedin and olaparib in patients with advanced and non-resectable bone and soft-tissue sarcomas (TOMAS): an open-label, phase 1b study from the Italian Sarcoma GroupGiovanni Grignani, Lorenzo D'Ambrosio, Ymera Pignochino, et al.
Pageof 3